This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.
Will you ACCELERATE Patient Outcomes?
Will you ACCELERATE Patient Outcomes?
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I'm Dr. Corey Casper. Here with me today is Dr. Sudipto Mukherjee and Jovanna, a patient that’s been diagnosed with Castleman’s disease.
So today, we're going to talk about patient advocacy networks. And these can be a huge asset in facilitating collaboration between patients and clinicians. So I'd like for both of you to share your perspectives on these patient advocacy networks and how they've helped you. So starting with Dr. Mukherjee, could you tell us a little bit about the overall benefits of these networks and your own personal experience with them?
Thank you, Dr. Casper. And I cannot emphasize enough how important it is to have a patient advocacy network, especially for rare diseases like Castleman disease. It's a rare disease, and to be able to advance the field, it is almost critical to establish a network of physicians and researchers across different institutions all over the world. And a shining example is the Castleman Disease Collaborative Network [CDCN], which was launched and is currently a global initiative that is dedicated to accelerating research and treatment for Castleman’s disease with the ultimate goal to improve survival. And it's possible only because this collaboration allows connection of the global research community, mobilizing resources, both scientific, laboratory, and financial resources, and then strategizing to invest in high-impact research, while at the same time supporting the patients and their loved ones through their clinical journey.
It also is of tremendous benefit because through these collaborative networks we can establish registries to understand the natural history of these diseases. It allows for collection of tissue and other biospecimens to advance research, and it is critically important in ensuring a faster and quicker accrual in clinical trials, which otherwise might take years or even decades if done by a single institution.
Finally, this provides a sounding board for other groups to join in and including the caregivers and patients’ families who can now be involved in shared decision-making on these patients.
From a personal standpoint, I have benefited enormously from being a part of CDCN, which is the patient advocacy group for Castleman’s disease. I have been able to contribute patients to the natural history registry, I've been able to contribute biospecimens to the registry for advanced research, and importantly, it has been instrumental in helping me manage several of my complicated patients, because I could get feedback and consultation through a wide variety of my colleagues spread all over the world who are a part of this network.
I would now ask Jovanna to share her personal experience with patient advocacy networks.
Thanks, Doctor. Yeah, so after my diagnosis, my doctors reached out to the CDCN, and that network has been a huge blessing in my journey with Castleman’s disease. I had answers to so many of the questions that had been bouncing around my head, and I finally felt heard and understood. I knew there was someone out there that was doing the work to make my life better and the lives of other Castleman disease patients better. And having a rare disease can make you feel very alone, but having the CDCN makes you feel like you have a whole community out there of people that are just like you. And it's given me lifelong friends who truly understand me and are doing great work. And I can't describe how much that network means to me.
Thanks, Jovanna, and thanks, Dr. Mukherjee. I think we heard very clearly from both of you that having these patient advocacy networks really allows for a sense of community and a true community to be built. And of course, we can do many great things together, much more than we can do alone.
So from Dr. Mukherjee, we heard that participating in these patient advocacy networks provides access to other clinicians with whom stories can be shared and solutions to difficult treatment options can be arrived at. Specimens can be shared in ways that can further research. And of course, because of the rareness of a disease like multicentric Castleman’s disease, participating in these patient advocacy networks allows for better clinical research to be done with a global community.
From Jovanna, we heard again, very clearly, that these patient advocacy networks provide a sense of community, a support, and resources to navigate what often can be a difficult and frustrating disease.
So that's been a great but brief discussion. Unfortunately, our time is up. Thanks for tuning in.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Corey Casper, MD, MPH
Clinical Professor of Medicine and Global Health
University of Washington
Affiliate Professor, Fred Hutch Cancer Center
Research: Amyris, ImmunityBio (IBRX), Janssen
Ownership Interest: Viracta Therapeutics
Receives Royalties: UpToDate
Patent Holder: AAHI
Consulting Fees: EUSA Pharma
Sudipto Mukherjee, MD, PhD, MPH
Director, Rare Cancers & Blood Diseases
Cleveland Clinic Taussig Cancer Institute
Research: BMS/Celgene, Jazz Pharma, Novartis
Receives Royalties: McGraw Hill
Consulting Fees: BioPharm, Blueprint Medicines, BMS/Celgene, Genentech and AbbVie, EUSA, Novartis
- Cindy Davidson has nothing to disclose.
- Stephen Chavez has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Mara Siegel has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Discuss the clinical burden and impact associated with a delayed diagnosis of Castleman disease
- Improve the speed and accuracy of a diagnosis of Castleman disease through increased recognition of its clinical presentation and knowledge of published diagnostic criteria
- Incorporate guideline-concordant care into the treatment of patients with Castleman disease
- Employ shared decision-making strategies to increase patient participation and promote advocacy, clinical trial enrollment, and research
This activity is designed to meet the educational needs of US hematologist oncologists, rheumatologists, infectious disease specialists, immunologists, and other HCPs who are involved in diagnosing, managing, and treating iMCD.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Recordati.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.